Abstract:Background: The improve sudden cardiac arrest (SCA) study was a nonrandomized prospective global study that identified a subset of primary prevention (PP) patients at an elevated risk for SCA labeled 1.5PP. These 1.5PP patients had one or more of the following additional risk factors: Syncope, nonsustained ventricular tachycardia, premature ventricular contractions >10/h, and left ventricular ejection fraction <25%. The purpose of this sub-analysis was to examine the China population cohort according to the improve SCA study's primary and secondary objectives. We aim to analyze the improve SCA study objective outcomes explicitly in the Chinese cohort to better understand the utility of PP implantable cardioverter-defibrillator (ICD) therapy in China. Subjects and Methods: The improve SCA study enrolled patients (n = 4222) during March 2014 and July 2017, including 87 sites in 17 countries from the geographies of Asia, Latin America, Eastern Europe, the Middle East, and Africa. In this analysis, the China cohort of improve SCA patients (n = 1654) was analyzed according to the objectives of the main study; the primary objective compared time to first appropriate ventricular tachycardia (VT) or ventricular fibrillation (VF) therapy between 1.5PP (n = 904) and secondary prevention (SP) patients (n = 470). All-cause mortality rates of 1.5PP with ICDs versus no implant, and an analysis of ischemic versus nonischemic results (n = 280) were also analyzed. PP patients without an additional risk factor were labeled 1.0PP (n = 280). Cox-proportional hazards model was used for hazard ratio (HR) calculations. This study was approved by the Ethics Committee of each participating institution and the associated national and local regulatory agencies, and registered with ClinicalTrials.gov (identifier: NCT02099721). Results: The time to first VT/VF therapy for 1.5PP was not within 30% of SP (HR = 0.42, 95% confidence interval [CI]: 0.31–0.56, P < 0.0001). However, there was a 49% reduction (HR = 0.51, 95% CI: 0.35–0.74, P = 0.0004) in all-cause mortality in the 1.5PP implanted versus nonimplanted patients, and a 70% reduction (HR = 0.30, 95% CI: 0.09–0.99, P = 0.05) in 1.0PP implanted patients. Nonischemic cardiomyopathy (NICM) 1.5PP patients showed a 51% reduction (HR = 0.49, 95% CI: 0.34–0.77, P = 0.0012) in all-cause mortality compared to those who did not receive an ICD implant. Conclusion: The China populations of 1.0PP and 1.5PP patients obtain a significant benefit with implantable defibrillation therapy.

Association Between Changes in Physical Activity and New-Onset Atrial Fibrillation After ICD/CRT-D Implantation

Implantable device measured objective daily physical activity as a predictor of long-term all-cause mortality and cardiac death in patients with age > 75 years and high risk of sudden cardiac death: a cohort study

Sex Differences in Physical Activity and Its Association With Cardiac Death and All-Cause Mortality in Patients With Implantable Cardioverter-Defibrillators

Implantable Cardioverter Defibrillators for Sudden Cardiac Death Prevention in China: A Regional Analysis from the Improve SCA Clinical Trial

Association of device-detected atrial high-rate episodes with long-term cardiovascular and all-cause mortality: a cohort study

Implantable cardioverter defibrillator therapy for primary prevention of sudden cardiac death: a single center experience

Abstract 14262: Atrial Fibrillation Burden and Clinical Outcomes in Patients With Cardiac Implanted Electronic Devices

Associations Between Changes in Maximum Daily Atrial Fibrillation Duration, Ischemic Stroke, and Mortality

Risk factors and prognosis of pacemaker-identified new-onset atrial fibrillation

Progression of Device-Detected Atrial High-Rate Episodes and the Risk of All-Cause Mortality

Association Between Atrial Fibrillation and Appropriate Implantable Cardioverter Defibrillator Therapy: Results from A Prospective Study

Multivariable analysis of incident ventricular tachycardia or ventricular fibrillation in patients with implantable cardioverter defibrillator

P6597Long-term Impact of Catheter Ablation on Growth Differentiation Factor-15 and Neutrophil-Lymphocyte Ratio in Paroxysmal Atrial Fibrillation

The mediation function of resting heart rate in how physical activity improves all-cause mortality: Continuous and automatic measurement via cardiac implantable electronic devices

Association of device detected atrial and ventricular tachyarrhythmia with adverse events in patients with an implantable cardioverter‐defibrillator

Retrospective Analysis on the Impact of Atrial Fibrillation in Patients with Implantable Cardioverter-Defibrillators

Implications of new-onset atrial fibrillation on in-hospital and long-term prognosis of patients with acute myocardial infarction: A report from the CBD bank study

Risk of Appropriate Implantable Cardioverter-Defibrillator Therapies and Sudden Cardiac Death in Patients With Heart Failure With Improved Left Ventricular Ejection Fraction

Atrial Fibrillation Burden Detected by Dual-Chamber Pacemakers As a Predictor for Cardiac Outcomes: A Retrospective Single-Center Cohort Study.

Comparison of the outcome between patients with new-onset atrial fibrillation and patients retained sinus rhythm after cardiac resynchronization therapy

Atrial fibrillation burden and heart failure: Data from 39,710 individuals with cardiac implanted electronic devices